COX-2 Expression in Atherosclerosis: The Good, the Bad or the Ugly?

Author(s): C. Cuccurullo, M. L. Fazia, A. Mezzetti, F. Cipollone.

Journal Name: Current Medicinal Chemistry

Volume 14 , Issue 15 , 2007

Become EABM
Become Reviewer

Abstract:

Cyclooxygenase (COX) is the rate limiting enzyme catalyzing the conversion of arachidonic acid into prostanoids, lipid mediators critically implicated in a variety of physiological and pathophysiological processes, including inflammation, vascular and renal homeostasis, and immune responses. Since the early 1990s it has been appreciated that two isoforms of COX exist, referred to as COX-1 and COX-2. Although structurally homologous, COX-1 and COX-2 are regulated by two independent and quite different systems and have different functional roles. In the setting of acute ischemic syndromes it has been recognized that COX pathway plays an important role; however, whereas the function of platelet COX-1 in acute ischemic diseases is firmly established, the role of COX-2 in atherothrombosis remains controversial. The complex role of COX-2 in this setting is also confirmed by the unexpected cardiovascular side effects of long-term treatment with COX-2 inhibitors. In this article, we review the pattern of expression of COX-2 in the cellular players of atherothrombosis, its role as a determinant of plaque vulnerability, the effects of the variable expression of upstream and downstream enzymes in the prostanoid biosynthesis on COX-2 expression and inhibition.

Keywords: Atherosclerosis, inflammation, arachidonic acid cascade, macrophages

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 15
Year: 2007
Page: [1595 - 1605]
Pages: 11
DOI: 10.2174/092986707780830998
Price: $58

Article Metrics

PDF: 3